About Keratin, type II cytoskeletal 7
Keratin, type II cytoskeletal 7 (KRT7) is a protein
from Homo sapiens identified by UniProt accession
P08729, 469 residues long.
MolForge cross-references it against 0 known binders and
618 disease associations.
Target properties
| Protein name | Keratin, type II cytoskeletal 7 |
| UniProt accession | P08729 |
| Gene | KRT7 |
| Organism | Homo sapiens |
| Length | 469 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (618)
Diseases linked to this target (Open Targets).
- prostate adenocarcinoma · score 0.19
- clear cell renal carcinoma · score 0.19
- head and neck squamous cell carcinoma · score 0.19
- breast adenocarcinoma · score 0.18
- neoplasm · score 0.12
- colorectal carcinoma · score 0.10
- cancer · score 0.10
- pancreatic adenocarcinoma · score 0.09
- inflammatory bowel disease · score 0.08
- hepatocellular carcinoma · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P08729-F1 | alphafold | PREDICTED | 73.60 | — |
Amino-acid sequence (469 residues)
MSIHFSSPVF TSRSAAFSGR GAQVRLSSAR PGGLGSSSLY GLGASRPRVA VRSAYGGPVG AGIREVTINQ SLLAPLRLDA DPSLQRVRQE ESEQIKTLNN KFASFIDKVR FLEQQNKLLE TKWTLLQEQK SAKSSRLPDI FEAQIAGLRG QLEALQVDGG RLEAELRSMQ DVVEDFKNKY EDEINHRTAA ENEFVVLKKD VDAAYMSKVE LEAKVDALND EINFLRTLNE TELTELQSQI SDTSVVLSMD NSRSLDLDGI IAEVKAQYEE MAKCSRAEAE AWYQTKFETL QAQAGKHGDD LRNTRNEISE MNRAIQRLQA EIDNIKNQRA KLEAAIAEAE ERGELALKDA RAKQEELEAA LQRGKQDMAR QLREYQELMS VKLALDIEIA TYRKLLEGEE SRLAGDGVGA VNISVMNSTG GSSSGGGIGL TLGGTMGSNA LSFSSSAGPG LLKAYSIRTA SASRRSARD
Explore Keratin, type II cytoskeletal 7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets